Please check your internet connection and try again.
# Durveqtix (fidanacogene elaparvovec-dzkt)
## Overview
Durveqtix is an adeno-associated virus vector-based gene therapy designed to deliver a functional copy of the *F9* gene to liver cells. It allows for endogenous production of Factor IX (FIX) in patients with hemophilia B, potentially eliminating the need for routine prophylactic factor replacement therapy.
## Primary Indications
Treatment of adults (≥18 years) with moderate-to-severe hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylactic therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
## Adult Dosing
A single intravenous infusion of 5 x 10¹¹ vector genomes (vg) per kilogram of body weight.
## Pediatric Dosing
Safety and efficacy have not been established in patients younger than 18 years. Use in pediatric populations is currently not recommended.
## Dose Adjustments
There is no provision for dose titration or repeat administration. Effectiveness of repeat administration has not been established.
## Contraindications
* Known hypersensitivity to fidanacogene elaparvovec-dzkt or any of its excipients.
* Active infections, either acute or uncontrolled chronic (e.g., untreated hepatitis B or C, HIV).
* Known advanced hepatic fibrosis or cirrhosis.
## Adverse Effects
* **Common:** Elevated liver enzymes (transaminitis), infusion-related reactions, headache, nausea, and fatigue.
* **Serious:** Hepatotoxicity (requiring corticosteroid management), potential for malignancy due to vector DNA integration (theoretically), and immune-mediated clearance of gene expression.
## Key Drug Interactions
* **Corticosteroids:** Often initiated prophylactically or emergently to manage vector-associated immune responses and transaminitis.
* **Hepatotoxic Agents:** Use with extreme caution as liver function monitoring is critical post-infusion; concomitant hepatotoxic drugs may complicate the assessment of vector-induced liver enzyme elevation.
## Monitoring
* **Liver Function:** ALT/AST levels must be monitored weekly for at least 3 months post-infusion to detect and manage immune-mediated hepatitis.
* **Factor IX Activity:** Periodic monitoring of Factor IX activity levels to ensure therapeutic response and monitor for declining activity.
* **Inflammatory markers:** Monitor for signs of systemic immune activation.
## Clinical Pearls
* **Hepatotoxicity Management:** Clinical protocols require a mandatory tapering course of corticosteroids (or other immunosuppressants) if liver transaminases exceed threshold levels, as this is critical to preventing the loss of the gene expression transgene.
* **Pre-infusion Screening:** Patients must be screened for pre-existing neutralizing antibodies to AAVRh74var capsid; those who test positive may not be candidates for this therapy.
* **Irreversibility:** As this is a permanent gene therapy, patients must be counseled that there is no "off-switch" should an adverse event occur. Response duration remains under long-term study.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical protocols and regulatory status may evolve. Always verify current prescribing information, institutional guidelines, and the FDA-approved labeling before clinical implementation. Consult with a specialized hematologist or specialty pharmacy for current regional policies.
